Home» Medical News

Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph Chronic Myeloid Leukemia
Views: 532
Date: 29 Jan 2012
Definition of medical terminology for Food.
Definition of medical terminology for Review.
Definition of medical terminology for Patients.
Definition of medical terminology for Philadelphia Chromosome.
Definition of medical terminology for Myeloid Leukemia.
Definition of medical terminology for Leukemia.
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for standard review of bosutinib as a treatment option for adult patients with previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).

Definition of medical terminology for Safety.
Definition of medical terminology for Patients.
Definition of medical terminology for Patients.
Definition of medical terminology for Patients.
Definition of medical terminology for Patients.
Definition of medical terminology for Leukemias.
Definition of medical terminology for Resistance Factors.
Definition of medical terminology for Filing.
Definition of medical terminology for Patient.
Definition of medical terminology for Populations.
Definition of medical terminology for Business.
Definition of medical terminology for Patients.
Definition of medical terminology for Kinase.
Definition of medical terminology for PDGFR beta.
Definition of medical terminology for Inhibition.
Definition of medical terminology for Tyrosine.
Not normal.
Definition of medical terminology for Mutation.
Definition of medical terminology for Tyrosine.
Definition of medical terminology for Kinase.
Definition of medical terminology for Inhibition.
Definition of medical terminology for Tyrosine.
Definition of medical terminology for Kinases.
Definition of medical terminology for Family.
Definition of medical terminology for Tyrosine.
Definition of medical terminology for Kinases.
Definition of medical terminology for Progression Free Survival.
Definition of medical terminology for Leukemias.
Definition of medical terminology for Patients.
Definition of medical terminology for Hematologic Malignancies.
Definition of medical terminology for Hematology.
Definition of medical terminology for Hematologic Malignancies.
Definition of medical terminology for Gene.
Definition of medical terminology for Resistance Factors.
Definition of medical terminology for Patients.

This submission was based on efficacy and safety data from Study 200, a single-arm study of bosutinib in over 500 patients with previously treated Ph+ CML, including patients resistant or intolerant to imatinib as well as patients who were previously treated with dasatinib or nilotinib. Currently, there are no approved therapies available for CML patients after second-line treatment with dasatinib or nilotinib.

CML, one of the four main types of leukemia,1 accounts for 15 percent of all leukemias worldwide.2 Despite the availability of existing treatments, there remains a need for additional options for CML patients, given observed treatmentarelated toxicities and resistance .

aThis filing underscores our commitment to bringing innovative treatment options to hematologic patient populations like CML, where the need for additional treatment options exists,a said Garry Nicholson, president and general manager of the Pfizer Oncology Business Unit. aWe are excited about the potential to bring this promising agent to those patients who fail or progress on previous therapies.a

Bosutinib is an oral, once-daily, investigational dual Src and Abl kinase inhibitor with minimal inhibitory activity against c-kit and PDGFR .3 It is believed that, by dual inhibition of the Src and Abl tyrosine kinases, bosutinib may inhibit signaling in CML cells that allows the cells to grow, survive and reproduce.4

A hallmark of CML is an abnormal chromosome known as the Philadelphia chromosome, a DNA mutation that initiates a series of events leading to the development of Bcr-Abl, a tyrosine kinase that causes CML cells to grow and reproduce rapidly.5 In some cases, resistance may develop to currently available therapies that inhibit Bcr-Abl.6 Inhibition of both Src and Abl tyrosine kinases may help overcome this resistance,7 as overexpression of the Src family of tyrosine kinases has been implicated in resistance and CML progression .4

Pfizer`s Commitment to Hematology

Hematologic cancers are a complex group of diseases, with over 70 different types of lymphomas, leukemias or myelomas. While there have been significant advancements in the treatment of some hematologic cancers, there continues to be a need for additional therapeutic options. Pfizer Oncology is committed to improving outcomes for patients living with hematologic malignancies like CML. Pfizer Oncology has a robust hematology pipeline, with biologics and small molecules in clinical development across a number of hematologic malignancies. We are advancing technologies as well as working to identify new and innovative options that address specific hematologic cancers, molecular subtypes, gene over-expression and mechanisms of resistance .

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.


Source : DrugsFreeList.com
Tags: chronic myeloid leukemia, bosutinib

Latest Medical News

» U.S. Food And Drug Administration Approves Pfizers INLYTA (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
-Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC)
29 Jan 2012 | Read


» Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph Chronic Myeloid Leukemia
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for standard review of bosutinib as a treatment option for adult patients with previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).
29 Jan 2012 | Read


» FDA approves Inlyta to treat patients with a type of advanced kidney cancer
The U.S. Food and Drug Administration approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.
29 Jan 2012 | Read


» FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)
The U.S. Food and Drug Administration (FDA) is informing the public that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML).
29 Jan 2012 | Read


» FDA. New and Generic Drug Approvals - January 27, 2012
New drugs approved. List of drugs approved by FDA to date January 27, 2012
29 Jan 2012 | Read


» FDA. New and Generic Drug Approvals - January 26, 2012
New drugs approved. List of drugs approved by FDA to date January 26, 2012
29 Jan 2012 | Read


» FDA. New and Generic Drug Approvals - January 25, 2012
New drugs approved.List of drugs approved by FDA to date January 25, 2012
29 Jan 2012 | Read


» FDA. New and Generic Drug Approvals - January 24, 2012
New drugs approved. List of drugs approved by FDA to date January 24, 2012
29 Jan 2012 | Read


» FDA. New and Generic Drug Approvals - January 23, 2012
New drugs approved.List of drugs approved by FDA to date January 23, 2012
29 Jan 2012 | Read


» FDA. New and Generic Drug Approvals - January 20, 2012
New drugs approved. List of drugs approved by FDA to date January 20, 2012
29 Jan 2012 | Read


» FDA. New and Generic Drug Approvals - January 19, 2012
New drugs approved. List of drugs approved by FDA to date January 19, 2012
29 Jan 2012 | Read


» FDA. New and Generic Drug Approvals - January 18, 2012
New drugs approved. List of drugs approved by FDA to date January 18, 2012
29 Jan 2012 | Read


» FDA expands use of endovascular graft to treat aortic tears
The U.S. Food and Drug Administration expanded the approved usage for an endovascular graft manufactured by W.L. Gore and Associates Inc. to include treatment of life-threatening tears or ruptures of the aorta (thoracic aortic transection).
19 Jan 2012 | Read


» FDA approves Voraxaze to treat patients with toxic methotrexate levels
The U.S. Food and Drug Administration approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure.
19 Jan 2012 | Read


» FDA Drug Safety Communication: New Boxed Warning and Contraindication for Adcetris (brentuximab vedotin)
The U.S. Food and Drug Administration (FDA) is notifying the public that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, have been reported with the lymphoma drug Adcetris (brentuximab vedotin).
19 Jan 2012 | Read


General Search

Last medical tags:


Torisel, temsirolimus, Inlyta, chronic myeloid leukemia, bosutinib, Inlyta, renal cell carcinoma, kidney cancer, myelin, Tysabri, natalizumab, brain infection, progressive multifocal leukoencephalopathy, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, thoracic aortic transection, endovascular graft, methotrexate, Voraxaze, cancer chemotherapy drug, glucarpidase, Adcetris, bleomycin, multifocal leukoencephalopathy, CardioGen-82, radiation, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, raltegravir, Isentress, antiretroviral medicines, Theravance, Relovair, asthma, fluticasone, bronchitis, neuromuscular disease, SMA, muscle atrophy, Resolor, prokinetic, prucalopride, ADHD, psychiatric behavioural disorder, Venvanse, lisdexamfetamine dimesylate, type 2 diabetes mellitus, Actoplus Met XR, pioglitazone, Mylan, Eprosartan Mesylate Tablets, Teveten, antimicrobials, cephapirin, cephalosporin, teriflunomide, Rebif, alanine aminotransferase levels, flu-like symptoms, multiple sclerosis, electrical pulses, implantable pulse generator, Precision Plus Spinal Cord Stimulator, genetic blood clotting disorder, hemophilia A, Advate, bleeding episodes, heart failure, heart transplantation, Pediatric Medical Device Safety, pulsatile cardiac assist device, selective serotonin reuptake inhibitor, SSRI, pulmonary hypertension,
» All tags  
Sitemap